文献速递胸部肿瘤

序贯放化疗后度伐利尤单抗治疗III期不可切除非小细胞肺癌:2期PACIFIC-6试验

Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
PubMed 文献 · J Thorac Oncol · 2022-08-09

PACIFIC-6是一项2期试验,评估序贯放化疗后度伐利尤单抗用于III期不可切除非小细胞肺癌的安全性与初步疗效。117例患者接受度伐利尤单抗1500 mg静脉注射每4周一次,最长24个月。6个月内可能与治疗相关的3或4级不良事件发生率为4.3%(95%CI 1.4-9.7),中位无进展生存期10.9个月(95%CI 7.3-15.6),12个月无进展生存率和总生存率分别为49.6%和84.1%。

要点

  • 序贯放化疗后度伐利尤单抗的安全性与PACIFIC中同步放化疗后度伐利尤单抗相当。
  • 6个月内可能与治疗相关的3或4级不良事件发生率为4.3%(95%CI 1.4-9.7),包括2例肺炎。
  • 中位无进展生存期10.9个月(95%CI 7.3-15.6),12个月总生存率84.1%。

核心结论

  • 序贯放化疗后度伐利尤单抗的安全性与PACIFIC中同步放化疗后度伐利尤单抗相当,且在较虚弱人群中显示出初步疗效。

研究设计与样本

  • 2期PACIFIC-6试验(NCT03693300)纳入III期不可切除非小细胞肺癌、铂类序贯放化疗后无进展的患者,接受度伐利尤单抗1500 mg静脉注射每4周一次,最长24个月。
  • 共纳入117例患者,其中59.8%体力状态评分>0,65.8%年龄≥65岁,37.6%为IIIA期。
  • 主要终点为6个月内可能与治疗相关的3或4级不良事件发生率;次要终点包括研究者评估的无进展生存期(实体瘤疗效评价标准1.1版)和总生存期。

主要发现

  • 中位治疗持续时间为32.0周;数据截止日期(2021年7月15日)时37.6%的患者仍在治疗中。
  • 3或4级不良事件发生于18.8%的患者;5例患者在6个月内发生可能与治疗相关的3或4级不良事件,发生率为4.3%(95%CI 1.4-9.7),包括2例肺炎。
  • 2例患者(1.7%)发生任何原因的5级不良事件;生存数据成熟度有限。
  • 中位无进展生存期为10.9个月(95%CI 7.3-15.6),12个月无进展生存率和总生存率分别为49.6%和84.1%。

关键数值与推荐

  • 6个月内可能与治疗相关的3或4级不良事件发生率为4.3%(95%CI 1.4-9.7)。
  • 中位无进展生存期为10.9个月(95%CI 7.3-15.6)。
  • 12个月无进展生存率为49.6%,12个月总生存率为84.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 生存数据成熟度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: On the basis of the findings of the phase 3 PACIFIC trial (NCT02125461), durvalumab is standard of care for patients with stage III, unresectable NSCLC and no disease progression after concurrent chemoradiotherapy (cCRT). Many patients are considered unsuitable for cCRT owing to concerns with tolerability. The phase 2 PACIFIC-6 trial (NCT03693300) evaluates the safety and tolerability of durvalumab after sequential CRT (sCRT). METHODS: Patients with stage III, unresectable NSCLC and no progression after platinum-based sCRT were enrolled to receive durvalumab (1500 mg intravenously) every 4 weeks for up to 24 months. The primary end point was the incidence of grade 3 or 4 adverse events possibly related to treatment occurring within 6 months. Secondary end points included investigator-assessed progression-free survival (PFS; Response Evaluation Criteria in Solid Tumors version 1.1) and overall survival. RESULTS: Overall, 117 patients were enrolled (59.8% with performance status >0, 65.8% aged ≥65 y, and 37.6% with stage IIIA disease). Median treatment duration was 32.0 weeks; 37.6% of patients remained on treatment at data cutoff (July 15, 2021). Grade 3 or 4 AEs occurred in 18.8% of patients. Five patients had grade 3 or 4 possibly related adverse events within 6 months (incidence: 4.3%; 95% confidence interval: 1.4-9.7), including two pneumonitis cases. Two patients (1.7%) had grade 5 AEs of any cause. Survival data maturity was limited. Median PFS was 10.9 months (95% confidence interval: 7.3-15.6), and 12-month PFS and overall survival rates were 49.6% and 84.1%, respectively. CONCLUSIONS: Durvalumab after sCRT had a comparable safety profile with that observed with durvalumab after cCRT in PACIFIC and had encouraging preliminary efficacy in a frailer population.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Garassino MC, Mazieres J, Reck M, et al. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022. PMID: 35961520. doi:10.1016/j.jtho.2022.07.1148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。